Kernalbio

Drug Discovery · Cambridge, MA · Founded 2016 · Privately Held (backing)

Developer of mRNA therapies designed to develop curative immunotherapies for cancers and COVID-19. Kernalbio is based in Cambridge, MA and was founded in 2016. It was valued at $111 million at its later-stage round in Jul 2022, the last priced event on record. It has raised $36.1 million across 1 recorded round; the latest was a $25 million Series A in Jul 2022.

PMV mark · valuation
$110.5M
Oct 2026
Priced at
its later-stage round
Jul 2022
Total raised
$36.1M
Last round
Later Stage VC (Series A)
Jul 2022

Who backs Kernalbio?

47 investors
InvestorType
Y CombinatorOther
MassChallenge—
Astir VenturesVenture capital
GaingelsVenture capital
Calm VenturesVenture capital
HOF CapitalVenture capital
Asymmetry VenturesVenture capital
Scale Asia VenturesVenture capital
Hummingbird VenturesOther
Ventioneers—
+ 37 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Kernalbio investors

47 investors are on record for Kernalbio, including Y Combinator, MassChallenge, Astir Ventures and Gaingels. By type, the record holds 6 venture capital firms. The Series A in Jul 2022 drew 20 investors.

Free account
More of Kernalbio with a free account
  • ·The complete investor list: 47 names
  • ·Watch Kernalbio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 47 firms already write checks for companies like Kernalbio in drug discovery. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View